
Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.








Published: September 24th 2020 | Updated:

Published: September 24th 2020 | Updated:

Published: September 24th 2020 | Updated:

Published: September 24th 2020 | Updated:

Published: September 24th 2020 | Updated:

Published: September 24th 2020 | Updated: